Aberdeen Group
AQST icon

Aberdeen Group’s Aquestive Therapeutics AQST Stock Holding History

Aberdeen Group’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-809,203
Closed -$5.23M – 938
2025
Q4 		$5.23M Buy
809,203
+184,203
+29% +$1.15M 0.01% 697
2025
Q3 		$3.49M Buy
+625,000
New +$2.7M 0.01% 732

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aberdeen Group's AQST Position: Q1 2026 in Review

Aberdeen Group sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 809,203 shares — an estimated $5.23M sold.

Aberdeen Group first reported a position in AQST in Q3 2025 and held it in 2 quarters. The position peaked at $5.23M in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Aberdeen Group reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aberdeen Group sold 809,203 Aquestive Therapeutics shares in Q1 2026, an estimated $5.23M.
  • Aberdeen Group first reported a position in Aquestive Therapeutics in Q3 2025 and held it in 2 quarters.
  • Aberdeen Group's Aquestive Therapeutics position peaked at $5.23M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.